Preoperative Nodal 18F-FDG Avidity Rather than Primary Tumor Avidity Determines the Prognosis of Patients with Advanced Gastric Cancer

다국어 초록 (Multilingual Abstract)

Purpose: This study investigated whether the metabolic avidity of primary tumors and/or metastatic lymph nodes (LNs) measured by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was related to survival after surgery in patients with advanced gastric cancer (AGC).
Materials and Methods: One hundred sixty-eight patients with AGC who underwent preoperative 18F-FDG PET/CT and curative resection were included. The 18F-FDG avidity of the primary gastric tumor and LNs was determined quantitatively and qualitatively. The diagnostic performance of 18F-FDG PET/CT was calculated, and the prognostic significance of 18F-FDG avidity for recurrence-free survival (RFS) and overall survival (OS) was assessed.
Results: In all, 51 (30.4%) patients experienced recurrence, and 32 (19.0%) died during follow-up (median follow-up duration, 35 months; range, 3–81 months); 119 (70.8%) and 33 (19.6%) patients showed 18F-FDG-avid primary tumors and LNs, respectively. 18F-FDG PET/CT showed high sensitivity (73.8%) for the detection of advanced pathologic T (pT ≥3) stage and high specificity (92.2%) for the detection of advanced pN (≥2) stage. 18F-FDG avidity of LNs was significantly associated with RFS (P=0.012), whereas that of primary tumors did not show significance (P=0.532). Univariate and multivariate analyses revealed that 18F-FDG avidity of LNs was an independent prognostic factor for RFS (hazard ratio=2.068; P=0.029).
Conclusions: 18F-FDG avidity of LNs is an independent prognostic factor for predicting RFS. Preoperative 18F-FDG PET/CT can be used to determine the risk and prognosis of patients with AGC after curative resection.

참고문헌 (Reference)

1 Kim EY, "The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT" 79 : 183-188, 2011

2 Abbas M, "The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice" 95 : 1082-1090, 2017

3 Songun I, "Surgical treatment of gastric cancer: 15- year follow-up results of the randomised nationwide Dutch D1D2 trial" 11 : 439-449, 2010

4 Lee JW, "Role of $^{18}F$-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection" 39 : 1425-1434, 2012

5 Lee JW, "Relationship between $^{18}F$-FDG uptake on PET and recurrence patterns after curative surgical resection in patients with advanced gastric cancer" 56 : 1494-1500, 2015

6 Cerfolio RJ, "Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer" 83 : 1826-1830, 2007

7 김정훈, "Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer" 대한핵의학회 48 (48): 33-40, 2014

8 Song BI, "Preoperative standardized uptake value of metastatic lymph nodes measured by $^{18}F$-FDG PET/CT improves the prediction of prognosis in gastric cancer" 94 : e1037-, 2015

9 김세훈, "Preoperative N Staging of Gastric Cancer by Stomach Protocol Computed Tomography" 대한위암학회 13 (13): 149-156, 2013

10 Maehara Y, "Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer" 87 : 353-357, 2000

11 Soret M, "Partial-volume effect in PET tumor imaging" 48 : 932-945, 2007

12 Lordick F, "PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial" 8 : 797-805, 2007

13 Ajani JA, "Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial" 28 : 1547-1553, 2010

14 Coupe NA, "Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer" 28 : 128-135, 2014

15 Ott K, "Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction" 24 : 4692-4698, 2006

16 Park J, "Lymph node to primary tumor SUV ratio by $^{18}F$-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer" 39 : e249-e253, 2014

17 Yun M, "Lymph node staging of gastric cancer using $^{18}F$-FDG PET: a comparison study with CT" 46 : 1582-1588, 2005

18 Japanese Gastric Cancer Association, "Japanese classification of gastric carcinoma: 3rd English edition" 14 : 101-112, 2011

19 Hwang SW, "Is endoscopic ultrasonography still the modality of choice in preoperative staging of gastric cancer?" 20 : 13775-13782, 2014

20 Dulak AM, "Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis" 72 : 4383-4393, 2012

21 Smyth EC, "Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up" 27 : v38-v49, 2016

22 Ajani JA, "Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology" 14 : 1286-1312, 2016

23 Baiocchi GL, "Follow-up after gastrectomy for cancer: an appraisal of the Italian research group for gastric cancer" 21 : 2005-2011, 2014

24 Stahl A, "FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings" 30 : 288-295, 2003

25 Mochiki E, "Evaluation of $^{18}F$-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer" 28 : 247-253, 2004

26 Ahn HS, "Diagnostic accuracy of T and N stages with endoscopy, stomach protocol CT, and endoscopic ultrasonography in early gastric cancer" 99 : 20-27, 2009

27 Ichikura T, "Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer" 11 : 1894-1900, 1993

28 Deng JY, "Clinical significance of lymph node metastasis in gastric cancer" 20 : 3967-3975, 2014

29 Siegel RL, "Cancer statistics, 2016" 66 : 7-30, 2016

30 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014" 대한암학회 49 (49): 292-305, 2017

31 Kim SK, "Assessment of lymph node metastases using $^{18}F$-FDG PET in patients with advanced gastric cancer" 33 : 148-155, 2006

32 Katanoda K, "An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013" 45 : 390-401, 2015

33 Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine" 357 : 1810-1820, 2007

34 Sarela AI, "Accurate lymph node staging is of greater prognostic importance than subclassification of the T2 category for gastric adenocarcinoma" 10 : 783-791, 2003

35 Smyth E, "A prospective evaluation of the utility of 2-deoxy-2-[$^{18}F$]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer" 118 : 5481-5488, 2012

36 Deng N, "A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets" 61 : 673-684, 2012

37 Washington K, "7th edition of the AJCC cancer staging manual: stomach" 17 : 3077-3079, 2010